About: Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies
Creator	Abinun, Mario Barge, Dawn Hambleton, Sophie Jackson, Anthony Nademi, Zohreh Gennery, Andrew Cant, Andrew Evans, Philippa Flood, Terry Lane, Jonathan Slatter, Mary
Source	Elsevier; Medline; PMC
abstract	Cord blood transplantation (CBT) is curative for many primary immunodeficiencies (PIDs) but is associated with risks of viral infection and graft-versus-host disease (GvHD). Serotherapy reduces GvHD but potentially increases the risk of viral infection by delaying immune reconstitution. Because many PID patients have pre-existing viral infections, the optimal dose of serotherapy is unclear. We performed a retrospective analysis in 34 consecutive PID patients undergoing CBT and compared immune reconstitution, viral infection, GvHD, mortality, and long-term immune function between high-dose (n = 11) and low-dose (n = 9) serotherapy. Serotherapy dose had no effect on neutrophil engraftment. Median CD3(+) engraftment occurred at 92.5 and 97 days for high- and low-dose serotherapy, respectively. The low-dose serotherapy group had higher CD3(+), CD4(+), and early thymic emigrant counts at 4 months compared with the high-dose group. GvHD severity and number of viral infections did not differ between serotherapy doses. Survival from the transplantation process was 90.9% for high-dose and 100% for low-dose groups. In conclusion, low-dose serotherapy enhanced T cell reconstitution and thymopoiesis during the first year after CBT with no increase in GvHD.
has issue date	2013-11-10(xsd:dateTime)
bibo:doi	10.1016/j.bbmt.2013.11.005
bibo:pmid	24225641
has license	no-cc
sha1sum (hex)	5fcad8178f6a40eeb46d4ecb0d590c4ebf4622c0
schema:url	https://doi.org/10.1016/j.bbmt.2013.11.005
resource representing a document's title	Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies
has PubMed Central identifier	PMC7110834
has PubMed identifier	24225641
schema:publication	Biol Blood Marrow Transplant
resource representing a document's body	covid:5fcad8178f6a40eeb46d4ecb0d590c4ebf4622c0#body_text
is schema:about of	named entity 'COMPARED' named entity 'PRIMARY' named entity 'PROCESS' named entity 'OCCURRED' named entity 'BUT' named entity 'CONSECUTIVE' named entity 'IMMUNE RECONSTITUTION' named entity 'EMIGRANT' named entity 'GROUP' named entity 'THYMOPOIESIS' named entity 'CURATIVE' named entity 'RISKS' named entity 'viral infections' named entity 'serotherapy' named entity 'serotherapy' named entity 'immune' named entity 'GvHD' named entity 'Transplantation' named entity 'IMMUNODEFICIENCIES' named entity 'VIRAL INFECTION' named entity 'GROUPS' named entity 'CORD BLOOD TRANSPLANTATION' named entity 'YEAR' named entity 'THYMIC' named entity 'DOSE' named entity 'GRAFT-VERSUS-HOST DISEASE' named entity 'RISK OF' named entity 'HIGH' named entity 'MEDIAN' named entity 'NO EFFECT' named entity 'RECONSTITUTION' named entity 'VIRAL INFECTIONS' named entity 'SEVERITY' named entity 'CBT' named entity 'CD3' named entity 'PREEXISTING' named entity 'RETROSPECTIVE ANALYSIS' named entity 'LOW-DOSE' named entity 'IMPROVES' named entity 'PRIMARY' named entity '100%' named entity 'UNCLEAR' named entity 'COUNTS' named entity 'IMMUNE FUNCTION' named entity 'ENHANCED' named entity 'CD4' named entity 'SEROTHERAPY' named entity 'PATIENTS' named entity 'ENGRAFTMENT' named entity 'CONCLUSION' named entity 'MORTALITY' named entity 'HAVE' named entity 'EARLY' named entity 'IMMUNE RECONSTITUTION' named entity 'SEROTHERAPY' named entity 'INCREASES' named entity 'DID' named entity 'CORD BLOOD TRANSPLANTATION' named entity 'DOSES' named entity 'MONTHS' named entity 'INCREASE' named entity 'HIGH-DOSE' named entity 'NEUTROPHIL ENGRAFTMENT' named entity 'OPTIMAL DOSE' named entity 'LONG-TERM' named entity 'TRANSPLANTATION' named entity 'ASSOCIATED WITH' named entity 'NUMBER OF' named entity 'IMMUNODEFICIENCIES' named entity 'EARLY' named entity 'T CELL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software